LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 130

Search options

  1. Article ; Online: Physicians' Dilemma of False-Positive RT-PCR for COVID-19: a Case Report.

    Roy, Sayak

    SN comprehensive clinical medicine

    2021  Volume 3, Issue 1, Page(s) 255–258

    Abstract: Coronavirus disease 2019 (COVID-19) has played havoc on this world's health and economics since its outbreak in December 2019. Reverse transcription-polymerase chain reaction (RT-PCR) has been the gold standard to diagnose severe acute respiratory ... ...

    Abstract Coronavirus disease 2019 (COVID-19) has played havoc on this world's health and economics since its outbreak in December 2019. Reverse transcription-polymerase chain reaction (RT-PCR) has been the gold standard to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Still, few false-positive reports are emerging up that add to the physicians' dilemma and maintenance of health statistics.
    Language English
    Publishing date 2021-01-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2947211-8
    ISSN 2523-8973 ; 2523-8973
    ISSN (online) 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-020-00655-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: COVID-19 Reinfection in the Face of a Detectable Antibody Titer.

    Roy, Sayak

    Cureus

    2021  Volume 13, Issue 3, Page(s) e14033

    Abstract: Coronavirus disease 2019 (COVID-19) reinfections are now reported from many countries with different coronavirus strains. Detectable immunoglobulin G (IgG) levels are thought to impart protective immunity to reinfection in that individual. Here, we ... ...

    Abstract Coronavirus disease 2019 (COVID-19) reinfections are now reported from many countries with different coronavirus strains. Detectable immunoglobulin G (IgG) levels are thought to impart protective immunity to reinfection in that individual. Here, we discuss a case report of a young, healthy, type 2 diabetic patient who suffered reinfection even after four times upper normal circulating IgG antibody specific to a COVID-19 spike protein. The first time was a clinical diagnosis when he self-isolated himself and was diagnosed later by COVID-19-specific symptoms with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)-specific IgG antibody titer.
    Language English
    Publishing date 2021-03-22
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.14033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: COVID-19 Reinfection: Myth or Truth?

    Roy, Sayak

    SN comprehensive clinical medicine

    2020  Volume 2, Issue 6, Page(s) 710–713

    Abstract: The novel coronavirus disease (COVID-19) has posed a large problem to this world and has exposed the skeleton of healthcare system all over. There have been reports of patients getting reinfected with COVID-19 as they tested positive for the virus again ... ...

    Abstract The novel coronavirus disease (COVID-19) has posed a large problem to this world and has exposed the skeleton of healthcare system all over. There have been reports of patients getting reinfected with COVID-19 as they tested positive for the virus again after discharge. We try to address the issue of this reinfection and want to clarify whether this entity actually exists or is it just a myth.
    Keywords covid19
    Language English
    Publishing date 2020-05-29
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2947211-8
    ISSN 2523-8973 ; 2523-8973
    ISSN (online) 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-020-00335-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg

    Sayak Roy

    Case Reports in Medicine, Vol

    An Indian Experience

    2020  Volume 2020

    Abstract: Background. Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD). There is no approved pharmacotherapy for NAFLD, and life-style ... ...

    Abstract Background. Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD). There is no approved pharmacotherapy for NAFLD, and life-style therapy plays a major role. Saroglitazar, the world’s first approved dual PPAR α/γ agonist, is approved in India for the treatment of diabetic dyslipidemia. The objective of this case series analysis was to evaluate the safety and effectiveness of saroglitazar 4 mg once daily in reducing liver stiffness in patients having diabetic dyslipidemia associated NAFLD. Method. In this retrospective case series analysis, we identified 10 patients with diabetic dyslipidemia (type 2 diabetes and triglycerides >200 mg/dL at baseline) and NAFLD who were treated with saroglitazar 4 mg once daily and the follow-up data were available for 9 months after saroglitazar treatment. At baseline, all patients were on stable antidiabetic and statin therapy. Liver stiffness was measured by using 2D shear wave elastography at baseline and at 9-month follow-up. Results. At 9-month follow-up after saroglitazar treatment, significant improvement was observed in shear wave velocity (SWV) and serum transaminases levels. Serum TG level was significantly reduced after 9-month treatment with saroglitazar. No major adverse event was reported. Conclusion. In this case series of 10 patients with diabetic dyslipidemia and NAFLD, saroglitazar improved liver stiffness along with reduction observed in liver enzymes and TG values. Long-term randomized controlled clinical trial is required to further establish the safety and efficacy of saroglitazar in treatment of NAFLD.
    Keywords Medicine ; R
    Subject code 610
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Hindawi Limited
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.

    Roy, Sayak

    Case reports in medicine

    2020  Volume 2020, Page(s) 4287075

    Abstract: Background: Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD). There is no approved pharmacotherapy for NAFLD, and life-style ... ...

    Abstract Background: Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD). There is no approved pharmacotherapy for NAFLD, and life-style therapy plays a major role. Saroglitazar, the world's first approved dual PPAR
    Method: In this retrospective case series analysis, we identified 10 patients with diabetic dyslipidemia (type 2 diabetes and triglycerides >200 mg/dL at baseline) and NAFLD who were treated with saroglitazar 4 mg once daily and the follow-up data were available for 9 months after saroglitazar treatment. At baseline, all patients were on stable antidiabetic and statin therapy. Liver stiffness was measured by using 2D shear wave elastography at baseline and at 9-month follow-up.
    Results: At 9-month follow-up after saroglitazar treatment, significant improvement was observed in shear wave velocity (SWV) and serum transaminases levels. Serum TG level was significantly reduced after 9-month treatment with saroglitazar. No major adverse event was reported.
    Conclusion: In this case series of 10 patients with diabetic dyslipidemia and NAFLD, saroglitazar improved liver stiffness along with reduction observed in liver enzymes and TG values. Long-term randomized controlled clinical trial is required to further establish the safety and efficacy of saroglitazar in treatment of NAFLD.
    Language English
    Publishing date 2020-03-27
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2502642-2
    ISSN 1687-9635 ; 1687-9627
    ISSN (online) 1687-9635
    ISSN 1687-9627
    DOI 10.1155/2020/4287075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: COVID-19 Reinfection

    Roy, Sayak

    SN Comprehensive Clinical Medicine

    Myth or Truth?

    2020  Volume 2, Issue 6, Page(s) 710–713

    Keywords covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2947211-8
    ISSN 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-020-00335-8
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Administration of Once-daily Canagliflozin to a Non-diabetic Patient in Addition to Standard Aerobic Exercise: A Case Report.

    Roy, Sayak

    Cureus

    2019  Volume 11, Issue 4, Page(s) e4352

    Abstract: There is no Indian data at present on sodium-glucose cotransporter 2 (SGLT2) inhibitors' role on glycated haemoglobin A1c (HbA1c), weight, and blood pressure in non-diabetic individuals. This novel mechanism of action could assure us of sustained non- ... ...

    Abstract There is no Indian data at present on sodium-glucose cotransporter 2 (SGLT2) inhibitors' role on glycated haemoglobin A1c (HbA1c), weight, and blood pressure in non-diabetic individuals. This novel mechanism of action could assure us of sustained non-glycaemic benefits along with information on the negligible risk of hypoglycaemia. The aim was to observe the changes of various parameters using canagliflozin (300 mg) in a non-diabetic person suffering from hypertension and dyslipidaemia (on treatment for two years). Canagliflozin (300 mg) once-daily was administered for 13 weeks with a continuous glucose monitoring system (CGMS) installed to assess glycaemic changes and tests done at baseline: four, eight, and 13 weeks. A dyslipidaemic and hypertensive with a family history of type 2 diabetes (T2D) (mother) and hypertension (father), the patient was currently using antihypertensive and statin therapy for two years. Over a period of 13 weeks, there was a reduction in weight by 3.2 kg; body mass index (BMI) by 1 Kg/m
    Language English
    Publishing date 2019-04-01
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.4352
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?

    Roy, Sayak

    Cureus

    2019  Volume 11, Issue 4, Page(s) e4361

    Abstract: Dengue is considered the most prevalent mosquito-borne viral disease worldwide and sometimes turns out to be life-threatening. Thrombocytopenia is frequently observed in mild and severe cases of dengue. Severe thrombocytopenia, with a platelet count much ...

    Abstract Dengue is considered the most prevalent mosquito-borne viral disease worldwide and sometimes turns out to be life-threatening. Thrombocytopenia is frequently observed in mild and severe cases of dengue. Severe thrombocytopenia, with a platelet count much below the normal range and hemorrhagic manifestation, is considered a fatal consequence of dengue that needs proper and timely management. The development of the dengue vaccine is quite challenging due to the existence of four different serotypes of the virus. Currently, neither a specific antiviral therapy nor a vaccine is available, and the common treatment modalities include fluid replacement therapy and platelet transfusions. Besides dengue, thrombocytopenia is correlated with many other diseases, particularly immune thrombocytopenic purpura (ITP). Thrombopoietin receptor (TPO-R) agonist, which is responsible for increasing platelet count, is a novel treatment option for chronic ITP patients. At present, two TPO-R agonists - eltrombopag and romiplostim - approved by the US Food and Drug Administration (USFDA) have been successfully used for the treatment of chronic ITP and other thrombocytopenic conditions. However, to date, only a single case study reported the use of romiplostim to enhance the platelet count in a myeloma patient suffering from dengue-associated thrombocytopenia. The objective of this review is to propose to the medical fraternity to consider using these TPO-R agonists to treat dengue hemorrhagic patients with thrombocytopenia and to conduct relevant researches to find out the usefulness of these molecules. This review is completely based on hypotheses and articles showing the positive response with romiplostim in dengue after going through a web-based search on various search engines. Furthermore, this review highlights the need for good-quality, randomized controlled trials and meta-analyses to detect the safety and efficacy of romiplostim and eltrombopag therapy for patients suffering from dengue-related thrombocytopenia.
    Language English
    Publishing date 2019-04-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.4361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: COVID-19 Reinfection: Myth or Truth?

    Roy, Sayak

    SN Compr Clin Med

    Abstract: The novel coronavirus disease (COVID-19) has posed a large problem to this world and has exposed the skeleton of healthcare system all over. There have been reports of patients getting reinfected with COVID-19 as they tested positive for the virus again ... ...

    Abstract The novel coronavirus disease (COVID-19) has posed a large problem to this world and has exposed the skeleton of healthcare system all over. There have been reports of patients getting reinfected with COVID-19 as they tested positive for the virus again after discharge. We try to address the issue of this reinfection and want to clarify whether this entity actually exists or is it just a myth.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #401424
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint

    Roy, Sayak

    SN Compr Clin Med

    Abstract: There are many reports available now, which are mostly observational or registry trial outcomes having varied results on coronavirus 2019 (COVID-19) patients put on hydroxychloroquine and azithromycin combination. Some are showing increased in-hospital ... ...

    Abstract There are many reports available now, which are mostly observational or registry trial outcomes having varied results on coronavirus 2019 (COVID-19) patients put on hydroxychloroquine and azithromycin combination. Some are showing increased in-hospital mortality and ventricular arrhythmia increase, while some are showing overall benefit with significant viral RNA load reduction. Everyday things are getting more complicated with the publication of these different outcomes. This needs to be addressed.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #617378
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top